Osanetant

Osanetant (SR-142,801) is a neurokinin 3 receptor antagonist developed by Sanofi-Synthélabo, which is being researched for the treatment of schizophrenia. It was the first non-peptide NK3 antagonist developed in the mid-1990s, and has still not made it to market, although clinical trials are continuing. Another potential application for osanetant is in the treatment of drug addiction, as it has been found to block the effects of cocaine in animal models.